Mode
Text Size
Log in / Sign up

Orlistat and semaglutide may improve ovulation and pregnancy rates in women with overweight or obesityWeight loss medications may help women with obesity achieve pregnancy

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider orlistat and semaglutide for improving pregnancy rates in women with overweight or obesity.

This meta-analysis evaluated the impact of weight-lowering drugs, specifically orlistat and semaglutide, on reproductive outcomes in women aged 25.9 to 29.7 years with overweight or obesity. The analysis synthesized data from 7 clinical trials involving a total of 575 participants.

Key findings indicate that orlistat was associated with higher ovulation rates compared to lifestyle modifications and a higher pregnancy rate (23.3% vs. 6.7%, p=0.044). When comparing orlistat to metformin, no significant difference in ovulation rates was observed (RR=0.78; 95% CI: 0.41-1.49; p=0.45). Furthermore, the addition of semaglutide to metformin resulted in an increased pregnancy rate compared to metformin alone (35% vs. 15%, p<0.05).

The authors note that current limitations are not specified but emphasize a need for adequately powered studies to confirm these findings. Clinical application is tempered by the lack of specific quantification regarding live birth rates and the general uncertainty regarding weight-lowering drugs without more robust trial data.

How this fits prior evidence

This meta-analysis extends prior evidence regarding semaglutide, which was previously noted as significantly reducing body weight in adults with obesity. While previous coverage established the efficacy of semaglutide for weight management and its role in NASH resolution, this study specifically addresses reproductive outcomes like ovulation and pregnancy rates in women with overweight or obesity. The findings also provide data on orlistat's impact on pregnancy compared to lifestyle modifications.

For many women struggling with weight, the journey to pregnancy can feel complicated by physical hurdles. New research looked at how specific weight-lowering medications might change those odds. The study focused on women aged 25 to 30 who were overweight or had obesity.

The data showed that women taking orlistat saw higher ovulation and pregnancy rates compared to those only making lifestyle changes. Additionally, adding the drug semaglutide to a metformin regimen resulted in a higher pregnancy rate than using metformin alone. These findings suggest these medications might offer more support than standard methods alone.

While the results are encouraging, it is important to remember that this data comes from a collection of smaller studies. The researchers noted that larger, more powerful studies are still needed to confirm these effects. Because everyone's health needs are unique, women should talk to their doctor about which options are safest and best for them.

What this means for you:
Specific weight-lowering drugs may improve ovulation and pregnancy rates for women with overweight or obesity.

Common questions

Can these medications help me get pregnant?

The study found that women taking orlistat had higher pregnancy rates compared to those only using lifestyle modifications. Specifically, the rate was 23.3% for orlistat versus 6.7% for lifestyle changes. However, because this is a meta-analysis of several trials, you should discuss these specific results with your doctor.

How does adding semaglutide affect pregnancy rates?

When semaglutide was added to metformin, the pregnancy rate increased from 15% to 35%. This suggests that combining certain weight-lowering medications might be more effective than using metformin alone. Your doctor can help determine if this combination is right for your specific health profile.

Is orlistat better than metformin for ovulation?

The study found no significant difference in ovulation rates between women taking orlistat and those taking metformin. While orlistat showed higher success compared to lifestyle changes alone, it performed similarly to metformin in terms of ovulation rates.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Overweight and obesity are global health concerns linked to impaired female fertility. Weight-lowering drugs are an alternative for achieving weight loss; however, their effect on natural female fertility is unclear. A systematic review and meta-analysis were conducted to summarise the literature on the effects of weight-lowering drugs on ovulation, conception, pregnancy and live birth rates. Inclusion criteria comprised interventional and observational studies involving women with overweight or obesity receiving weight-lowering drugs, compared with non-users, lifestyle modifications or other medications. MEDLINE, Embase, CINAHL, CENTRAL and ClinicalTrials.gov were searched, yielding 2731 records. After screening, seven clinical trials were included (n = 575), six of which were randomised. Sample sizes ranged from 40 to 120 women aged 25.9-29.7 years. Six trials evaluated orlistat, while one assessed semaglutide. In four trials, orlistat was associated with a higher ovulation rate than lifestyle modifications. A meta-analysis of ovulation rates comparing orlistat and metformin showed no significant difference (RR = 0.78, 95% CI: 0.41-1.49; p = 0.45). Two studies reported pregnancy rates: one found a higher rate with orlistat compared to lifestyle modifications (23.3% vs. 6.7%, p = 0.044), and another showed that adding semaglutide to metformin increased the pregnancy rate compared to metformin alone (35% vs. 15%, p < 0.05). Future studies should address current limitations and evaluate the effects of newer weight-lowering drugs on natural pregnancy and live birth rates in adequately powered studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.